PRLD Projected Dividend Yield

Prelude Therapeutics Inc ( NASDAQ : PRLD )

Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.

20 YEAR PERFORMANCE RESULTS